(S)-Carvedilol (C007B-342808)

(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100 times greater than that of (R)-Carvedilol, whereas both enantiomers show equipotent potency as α-blockers. (S)-Carvedilol significantly attenuates Doxorubicin (DOX)-induced cell death, apoptotic morphological changes, decrease the mitochondrial membrane potential and oxidative stress responses by increasing the superoxide dismutase and catalase activities, and decreasing malondialdehyde contents and reactive oxygen species levels via the PI3K/AKT/eNO synthase pathway in vitro. (S)-Carvedilol treatment significantly upregulates the expression levels of p-eNOS in HUVECs. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:β/α-1 adrenergic receptor.

Specifications and Purity: ≥99%

Molecular Formula: C24H26N2O4

Molecular Weight: 406.47

PubChem CID: 185395

Isomeric SMILES: COC1=CC=CC=C1OCCNC[C@@H](COC2=CC=CC3=C2C4=CC=CC=C4N3)O